Network News

X My Profile
View More Activity

Stem Cells - Back by Popular Demand

Updated, 11:15 a.m.

Eager to turn the page on downbeat coverage of the economy, President Obama appears poised to tackle an issue that's had consistent and broad public support - reversing his predecessor's restrictions on federally-funded stem cell research.

But while lifting these limits has widespread support, the move will likely further rankle some in the GOP. In a January Washington Post-ABC News poll, 59 percent of Americans said they supported loosening the current restrictions, with support topping 60 percent among both Democrats and independents. Most Republicans, however, stood in opposition (55 percent opposed; 40 percent in support).

At the same time, the issue may prove more divisive within the GOP than between Obama and the opposition. Conservative Republicans are widely against easing the restrictions (71 percent opposed), but moderate and liberal Republicans back the change by a 57 to 37 percent margin.

Here's more breakdown from the January Post-ABC poll...

Q: Do you support or oppose loosening the current restrictions on federal funding for embryonic stem cell research?

              Support   Oppose   No opinion
All adults      59        35         6

Democrats       68        26         6
Republicans     40        55         5
Independents    64        30         6

Liberal Dem.    74        21         5
Mod./Con. Dem.  63        31         6

Lib./Mod. Rep.  57        37         6
Cons. Rep.      26        71         4

By Jon Cohen  |  March 9, 2009; 11:15 AM ET
Categories:  Post Polls  
Save & Share:  Send E-mail   Facebook   Twitter   Digg   Yahoo Buzz   StumbleUpon   Technorati   Google Buzz   Previous: Newt in 2012?
Next: Cellphones: New State-Level Estimates


The largest stem cell breakthrough on Monday is going to be more with Advanced Cell Technology than with any other more recognized company, in terms of price jump, as they own 400 of the key patents and for example license patents to GERON. has products in the clinical stages I and II for retina repair, diabetes/pancreas repair, and repair of heart tissue after heart attacks.

Stephen Fox, Editor, New Mexico Sun News
Santa Fe, New Mexico

Posted by: stephen6 | March 6, 2009 5:49 PM | Report abuse

The comments to this entry are closed.

RSS Feed
Subscribe to The Post

© 2010 The Washington Post Company